Review Article

Prevalence of Metabolic Syndrome among Iranian Population: A Systematic Review and Meta-analysis

Sahar DALVAND¹, Seyed Hassan NIKSIMA², Reza MESHKANI³, Reza GHANEI GHESHLAGH⁴, Sahar SADEGH-NEJADI³, Wesam KOOTI⁵, Naser PARIZAD⁶, Hossein ZAHEDNEZHAD⁷, *Reza AFRISHAM³

¹. Social Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran
². Dept. of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
³. Dept. of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
⁴. Dept. of Nursing, Faculty of Nursing and Midwifery, Kurdistan University of Medical Sciences, Sanandaj, Iran
⁵. Research Committee, Kurdistan University of Medical Sciences, Sanandaj, Iran
⁶. Dept. of Medical-Surgical Nursing, School of Nursing and Midwifery, Tabriz University of Medical Sciences, Tabriz, Iran
⁷. Dept. of Nursing, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran

*Corresponding Author: Email: rezaafrisham@yahoo.com
(Received 11 Sep 2016; accepted 22 Feb 2017)

Abstract

Background: Metabolic syndrome (MetS) is the major risk factor for development of type 2 diabetes and cardiovascular diseases in different populations. The aim of this study was to evaluate the prevalence of MetS among Iranian population.

Methods: Thirty-four cross-sectional studies were analyzed with a sample of 83227 people. National and international English electronic databases (PubMed, Google scholar, Web of Science, Science Direct, and Scopus) and Persian language databases (SID, Medlib, Iran medex, Magiran, Medlib, and IranDoc) were used to search the articles published on MetS in Iranian population from Jan 2005 to May 2016. The MetS diagnosis was performed according to the ATP-III, NCEP/ATP-III, IDF and WHO criteria.

Results: The overall weighted prevalence of MetS was 31% (95% CI: 28-35). According to ATP III criteria, total and gender-stratified prevalence of MetS in women and men were 29% (95% CI: 22-36), 37% (95% CI: 26-48) and 29% (95% CI: 23-36), respectively. Total prevalence of MetS based on NCEP/ATP III criteria was 29% (95% CI: 24-35) that the prevalence was 24% (95% CI: 18-30) and 35% (95% CI: 25-44) in men and women, respectively. According to the IDF and WHO criteria, total prevalence of MetS were 38% (95% CI: 32-43) and 30% (95% CI: 7-53), respectively.

Conclusion: The findings demonstrate an emerging high prevalence of MetS in total and in particular among Iranian women population. Therefore, to minimize the risk of cardiovascular events in Iranian population, screening and early detection of risk factors for MetS are required.

Keywords: Metabolic syndrome, Prevalence, Meta-analysis, Systematic review, Iran

Introduction

Metabolic syndrome (MetS) is a collection of different cardiovascular risk factors such as dyslipidemia, hypertension, abdominal obesity and diabetes (1). The concept of MetS has existed for at least 80 yr (2). MetS was first described as X syndrome (3). MetS is linked with several
The prevalence of MetS is increasing globally (5). In Western countries, 23% of the population suffers from this syndrome (6). According to the International Diabetes Federation criteria, one in four adults in the world has MetS. The risk of death, stroke and heart attacks is two to three times more in subjects with MetS compared to individuals without this syndrome (7). More importantly, the prevalence of this disorder is increasing in children and young adults worldwide (8). MetS have five essential components, including obesity/abdominal obesity, high blood pressure, low high-density lipoprotein cholesterol (HDL-C), elevated triglycerides and hyperglycemia. Several definitions have been proposed for MetS and the most commonly used are the Adult Treatment Panel III (ATP-III) and adapted ATP-III criteria (NCEP / ATP-III-A) (9, 10) by the National Cholesterol Education Program (NCEP), the International Diabetes Federation (IDF) (11) and the World Health Organization (WHO) criteria (12).

Methods

Search strategy
We searched International databases (PubMed, Google scholar, Web of Science, Science Direct and Scopus) and Persian national databases [SID (Scientific Information Database), Medlib (Iranian Medical Library), Iran Medex (articles published in Iran Biomedical Journals), Magiran and IranDoc] for published articles concerning the MetS in Iranian population. The current research was performed using medical subject headings (MeSH) terms and the combination of keywords including: “metabolic syndrome”, “dysmetabolic syndrome”, ”insulin resistance syndrome” with the words “prevalence” and “Iran”. The Persian equivalent of these terms and all possible combinations in the Persian national databases were searched. Articles with English abstract were also used.

Study selection
Initially, a list of the titles and abstract of all papers contained in databases was prepared to evaluate the relevant titles. Comply with the inclusion criteria; the cross-sectional studies that estimate the prevalence of MetS among Iranian population from Jan 2005 to May 2016 were included in the current research. To assess the eligibility and inclusion criteria, articles were evaluated by two independent reviewers. In the articles, MetS diagnosis was performed according to ATP-III [9], NCEP / ATP-III [10], IDF [11] and WHO [12] criteria. Table 1 shows common definitions of MetS used in the present study.

Exclusion criteria in this study were: 1) studies with no original research (reviews, editorials, non-research letters); 2) case reports and case series; 3) studies with non-random sampling method; 4) studies including subjects with hemochromatosis, chronic liver disease, and liver cirrhosis; 5) studies including pregnant women; 6) insufficient data; 7) non-standardized diagnosis; and 8) studies published in Persian without an English abstract.

Overall, 34 related articles were reviewed. Then, the desired data were accurately obtained using a data extraction form on the basis of title, year of publication, type of study, region (province), sample size, the definition used for MetS, gender, and four different criteria for MetS definition. The present study was performed based on PRISMA guideline (Preferred reporting items for systematic reviews and meta-analysis) (20).
Table 1: Common definitions of metabolic syndrome

| ATP III Definition          | NCEP / ATP III Definition | IDF Consensus Definition | WHO                              |
|-----------------------------|---------------------------|--------------------------|----------------------------------|
| (3 of 5 Required)           | (3 of 5 Required)         | (Waist Plus 2 Required)  |                                  |
| **Waist circumference**     |                           |                          |                                 |
| Men > 102 cm (>40 in)       | Men > 102 cm (>40 in)     | Male ≥ 94 cm (>37 in)    | BMI >30 kg/m², or WHR >0.9 in male and >0.85 in female |
| Women > 88 cm (>35 in)      | Women > 88 cm (>35 in)    | Female ≥ 80 cm (>31.5 in)| Plus two or more of the following: |
| Blood pressure              |                           |                          |                                 |
| Systolic / diastolic        | ≥130 / ≥85 mmHg           | ≥130/≥85 mmHg            | ≥140 / ≥90 mmHg                  |
| HDL cholesterol             |                           |                          |                                 |
| Men < 40 mg/dl (1.03 mmol/l)| Men < 40 mg/dl (1.03 mmol/l)| Men < 40 mg/dl (1.03 mmol/l)| Men < 35 mg/dl (0.9 mmol/L)     |
| Women < 50 mg/dl (1.29 mmol/l)| Women < 50 mg/dl (1.29 mmol/l)| Women < 50 mg/dl (1.29 mmol/l)| Women < 39 mg/dl (1 mmol/L)    |
| Triglycerides               | ≥150 mg/dl (1.7 mmol/l)   | ≥150 mg/dl (1.7 mmol/l)  | ≥150 mg/dl (1.7 mmol/l)          |
| Fasting glucose             | ≥110 mg/dl (6.1 mmol/l)   | ≥100 mg/dl (5.6 mmol/l)  | Diabetes or impaired glucose tolerance (2-h post load plasma glucose ≥7.8 mmol/L) |

BMI = Body Mass Index  
WHR = Waist to Hip Ratio

**Meta-analysis**

Point estimates and their 95% confidence intervals (CI) of the prevalence of MetS was calculated using random-effects model (DerSimonian and Laird’s) and presented in a Forest plot to visualize the heterogeneity among studies. The variance of MetS prevalence in each study was calculated with respect to binomial distribution formula. To study the potential publication bias, assess small study effects, Egger regression test, and funnel plot were used. The Cochran Q test was used to investigate the heterogeneity among studies ($P >0.1$ was significant).

The $I^2$ index was used to assess the percentage of variation across the studies due to heterogeneity rather than the chance. A value of 0% indicates no observed heterogeneity, while 100% indicates a significant heterogeneity. (Values of 25%, 50%, and 75% were considered representing low, medium and high heterogeneity, respectively). In this study, $I^2$ values above 75% were used to show a significant heterogeneity (21, 22). Furthermore, we tested the heterogeneity among subgroups using meta-regression analysis. In addition, meta-regression test was applied to evaluate the relationship between the prevalence of MetS, the year of publication, and the study sample size. Furthermore, we stratified included studies by diagnostic criteria (ATP III, NCEP/ATP III, IDF, WHO) and overall prevalence was estimated according to four definitions. We tested the heterogeneity among subgroups using meta-regression analysis. For the purpose of meta-analysis, included studies were assumed random samples from studies population. The meta-analysis was performed with STATA software ver. 12.0.

**Results**

Based on inclusion criteria, 34 cross-sectional studies out of 921 studies had eligibility to be included in current systematic review and meta-analysis and analyzed with a sample of 83227 subjects. Studies including 80 (23) and 12514 subjects (24) were the smallest and largest sample size included in the analyses. The articles included in the meta-analysis were different according to each MetS criteria. The results of this study indicated the possibility of statistically significant bias using Egger regression test ($P=0.023$). Heterogeneity of the samples was examined by Cochran $Q$ test and $I^2$ index. The heterogeneity of the samples was significant with $Q=7987.63$ ($P<0.001$) and $I^2$
index was 99.4% (P<0.001). According to diagnostic criteria total prevalence of MetS was 29% (95% CI: 22-36) and 29% (95% CI: 24-34) based on ATP III criteria and NCEP /ATPIII criteria, respectively. In addition, based on IDF and WHO criteria, total prevalence of MetS were 38% (95% CI: 32-43) and 30% (95% CI: 7-53), respectively. In this Meta-analysis, common definitions of metabolic syndrome are presented in Table 1. Table 2 shows the results of the prevalence of MetS according to various diagnostic criteria.

Table 2: The prevalence of metabolic syndrome in studies based on various diagnostic criteria

| First author | Year | City (Geographical region) | Age | Gender | Diagnostic criteria | Sample size (n) | Prevalence (%) | Confidence interval 95% |
|--------------|------|---------------------------|-----|--------|--------------------|----------------|----------------|------------------------|
| Jalali R (53) | 2009 | Khorasan (2)              | 19< | Female/male | ATP III             | 1402           | 25.6           | 23-28                  |
| Sadrbafghi SM (54) | 2006 | Yazd (5)                  | 20-74 | Female/male | ATP III             | 1110           | 32.1           | 29-35                  |
| Gherghereh-chi R (55) | 2010 | Tehran (1)               | 4-18 | Child/teenager | ATP III            | 235            | 31.9           | 26-38                  |
| Shahbazian H (17) | 2013 | Ahvaz (4)                 | 20-70 | Female/male | ATP III             | 912            | 22.8           | 20-26                  |
| Javadi H (56) | 2014 | Qazvin (1)                | 24< | Female/male | ATP III             | 956            | 33             | 30-36                  |
| Marjani A (57) | 2011 | Gorgan (1)               | Uncertain | Female/male | ATP III | 200 | 51.5 | 54-58 |
| Sharifi F (16) | 2009 | Zanjan (3)               | 20< | Female/male | ATP III         | 2941           | 23.7           | 22-25                  |
| Jouyandeh Z (58) | 2013 | Tehran (1)               | Uncertain | Postmenopausal women | ATP III | 118 | 30.1 | 22.38 |
| Hadaegh F (59) | 2009 | Tehran (1)               | 65< | Female/male | ATP III            | 720            | 50.8           | 47-54                  |
| Maharluiee N (60) | 2013 | Shiraz (2)                | 40< | Female/Pre-menopause | ATP III | 490 | 30 | 26-34 |
| Mehrabpour M (61) | 2007 | Rafsanjan (5)            | 11-18 | Female | ATP III | 1221 | 3.9 | 3.5 |
| Mardani M (61) | 2015 | Khorramabad (4)          | 19-27 | Female/male | ATP III | 214 | 1.9 | 0.1-7.3 |
| Jalalzadeh M (23) | 2011 | Zanjan (3)               | 16< | Female/male | ATP III | 80 | 28.7 | 19-39 |
| Sarrafaaeghian N (62) | 2011 | Isfahan (2)             | 19< | Female/male | ATP III | 9570 | 22.5 | 22-23 |
| Kaykhaii M (63) | 2012 | Zahedan (5)              | 19< | Female/male | NCEP/ATPIII   | 1802           | 21            | 19-23                  |
| Fakhraieh H (64) | 2006 | Tehran (1)               | 25-64 | Female/male | NCEP/ATPIII | 1480 | 27.5 | 25-30 |
| Foroozanfar Z (65) | 2015 | Kerman (5)               | Uncertain | Female/male | NCEP/ATPIII | 950 | 73.4 | 71-76 |
| Keykhah M (66) | 2013 | Isfahan (2)              | 30-60 | Female/male | NCEP/ATPIII | 3228 | 35.8 | 34-37 |
| Rashdi H (49) | 2014 | Ahvaz (4)                | 10-19 | Female/male | NCEP/ATPIII | 2246 | 9 | 8-10 |
| Marjani A (67) | 2012 | Gorgan (1)              | 20< | Female | NCEP/ATPIII | 160 | 20.6 | 14-27 |
| Esmaeili Asgari N (68) | 2012 | Kurdistan (3)       | 25-64 | Female/male | NCEP/ATPIII | 1194 | 29.1 | 27-32 |
| Zabarian A (42) | 2007 | Tehran (1)               | 20< | Female/male | NCEP/ATPIII | 10368 | 33.2 | 32-34 |
| Marjani A (69) | 2012 | Gorgan (1)              | >45 | post-menopause | NCEP/ATPIII | 100 | 31 | 22-40 |
| Ostovaneh M (70) | 2014 | Zahedan (5)             | 16< | Female/male | NCEP/ATPIII | 2243 | 12 | 11-13 |
| Marjani M (70) | 2014 | Sistan (1)              | 30-70 | Female/male | NCEP/ATPIII | 3799 | 28.5 | 27-30 |
| Hajar-Talab K (37) | 2014 | Babol (1)                | 20-70 | Female/male | NCEP/ATPIII | 1000 | 42.3 | 39-45 |
| Tabatabaei AH (72) | 2015 | Shiraz (2)            | 20< | Female/male | NCEP/ATPIII | 377 | 26.8 | 22-31 |
| Saberi H (19) | 2009 | Kashan (2)              | 30< | Man driver | NCEP/ATPIII | 429 | 35.9 | 31-40 |
| Delvar MA (50) | 2009 | Babol (1)                | 30-50 | Female | NCEP/ATPIII | 916 | 31 | 28-34 |
| Majdouj S (73) | 2012 | Babol (1)                | 20< | Female/male | NCEP/ATPIII | 933 | 23.7 | 21-26 |
| Moiini A (74) | 2012 | Tehran (1)              | 15-40 | Female/male | NCEP/ATPIII | 282 | 23 | 18-28 |
| Ebrahimi-Mameghani M (75) | 2011 | Tabriz (3)               | Uncertain | Male firefighter | IDFS | 76 | 56.6 | 45-68 |
| Moberlibi I (76) | 2012 | Zanjan (3)             | 20-67 | Man driver | IDFS | 12138 | 32.4 | 32-33 |

Available at: [http://ijph.tums.ac.ir](http://ijph.tums.ac.ir)
The highest and lowest prevalence of MetS were found in Kerman 73.4% (95% CI: 71-76) and Khorramabad 1.9% (95% CI: 0.1-7.3), respectively. Table 3 shows the prevalence of MetS according to gender and age (less and more than 19 yr of age) groups. On basis ATP III criteria, women and men had a prevalence of 37% (95% CI: 26-48) and 29% (95% CI: 23-36), respectively. Based on the NCEP /ATP III criteria, the prevalence of MetS were 24% (95% CI: 18-30) and 35% (95% CI: 25-44) men and women groups, respectively. Also, the prevalence of MetS at ages less than 19 yr and the age group above 19 yr were 18% (CI 95%: 12%-25%) and 31% (CI 95%: 28%-34%), respectively.

Table 3: The prevalence of metabolic syndrome according to gender and age in the meta-analysis

| Diagnostic criteria | Number of studies | Prevalence % | Confidence interval | Homogeneity (I²) | P-value |
|---------------------|------------------|--------------|---------------------|-----------------|---------|
| **women**           |                  |              |                     |                 |         |
| 11                  | 37               | 26-48        | 99.5                |                 |         |
| men                 |                  |              |                     |                 |         |
| 8                   | 29               | 23-36        | 97.1                |                 |         |
| PP gender           |                  |              |                     |                 |         |
| 19                  | 34               | 27-41        | 99.2                |                 |         |
| age < 19            | ATP III          | 2            | 17                  | 10-45           | 98.8    | P <0.001 |
| age ≥ 19            | 9                | 29           | 91                  |                 |         |
| PP age              | 11               | 27           | 99.4                |                 |         |
| women               | 12               | 35           | 99.5                |                 |         |
| men                 | 13               | 24           | 98.8                |                 |         |
| PP gender           | NCEP/ATP III     | 25           | 29                  | 24-35           | 99.4    | P <0.001 |
| age < 19            | 4                | 17           | 99.5                |                 |         |
| age ≥ 19            | 12               | 29           | 97.7                |                 |         |
| PP age              | 16               | 26           | 99.2                |                 |         |
| women               | 6                | 42           | 99.5                |                 |         |
| men                 | 7                | 32           | 98.9                |                 |         |
| PP gender           | IDF              | 13           | 37                  | 31-43           | 99.3    | P <0.001 |
| age < 19            | 3                | 21           | 99.3                |                 |         |
| age ≥ 19            | 6                | 36           | 99.4                |                 |         |
| PP age              | 9                | 32           | 99.1                |                 |         |
| women               | 1                | 47           | 41-52               | --              |         |
| men                 | 1                | 38           | 34-43               | --              |         |

‡ Pooled prevalence

Table 4 shows subgroups analysis of the prevalence of MetS in different regions across the diagnostic criteria. Based on geography classification, Iran is divided into 5 regions. Region 1 includes the provinces of Tehran, Qazvin, Golestan, Mazandaran, Semnan, Alborz, and Qom. Region 2 contains Isfahan, Fars, Bushehr, Chaharmahal and Bakhtiari, Hormozgan and Kohkiluyeh and Boyerahmad provinces. Region 3 covers East Azerbaijan, West Azerbaijan, Ardabil, Zanjan, Gilan and Kurdistan provinces. Region 4 includes Kermanshah, Ilam, Lorestan, Hamadan, Markazi and Khuzestan provinces, and region 5 contains Razavi Khorasan, South Khorasan, North Khorasan, Kerman, Yazd and Sistan-Baluchestan provinces (25). Total prevalence of MetS in the region 1, 2, 3, 4 and 5 were 31% (CI 28-35%), 33% (CI 29-36%), 33% (CI 21-45%), 11% (CI 2-20%) and 38% (CI 20-56%), respectively (Table 4). Based on meta-regression test, the prevalence of MetS is reduced by increasing the sample size. Due to the positive slope of the meta-regression line and P-value=0.175, the prevalence of MetS has no significant relation with the sample size in Iran. Furthermore the prevalence of MetS is increased with increasing the year of the study, but the difference was not statistically significant (P=0.604).
Available at: http://ijph.tums.ac.ir

**Table 4: Subgroup analysis for comparison of prevalence in different region across diagnostic criteria**

| Region | Method | No. of studies | Prevalence (95% CI) | I²% | Heterogeneity test | Egger test |
|--------|--------|----------------|---------------------|-----|--------------------|------------|
|        |        |                | Q                   | P   | t                  | P          |
|        |        |                |                     |     |                    |            |
|        |        |                |                     |     |                    |            |
| ATP III | 5      | 40 (30-49)     | 94.9                | 78.55 | P<0.001            | 0.12       | 0.911     |
| NCEP   | 10     | 29 (26-32)     | 94.7                | 169.49 | P<0.001            | 0.74       | 0.480     |
| 1      | IDF    | 5              | 30 (21-38)          | 99.5 | 806.62             | P<0.001    | 0.15       | 0.891     |
| WHO    | 2      | 30 (7-53)      | 99.4                | 155.40 | P<0.001            | ---        | ---        |
| Total  | 22     | 31 (28-35)     | 98.9                | 1922 | P<0.001            | 1.54       | 0.138     |
| ATP III| 4      | 32 (23-41)     | 98                  | 151.1 | P<0.001            | 2.30       | 0.148     |
| 2      | NCEP   | 5              | 30 (24-37)          | 98.1 | 214.11             | P<0.001    | 1.42       | 0.250     |
| IDF    | 3      | 38 (26-51)     | 97.2                | 72.72 | P<0.001            | 1.17       | 0.449     |
| Total  | 12     | 33 (29-36)     | 98.0                | 544.04 | P<0.001            | 3.71       | 0.004     |
| ATP III| 3      | 18 (22-35)     | 99.5                | 438.15 | P<0.001            | 0.47       | 0.721     |
| 3      | NCEP   | 1              | 29 (27-32)          |     |                    | ---        | ---        |
| IDF    | 3      | 49 (28-70)     | 95.2                | 41.40 | P<0.001            | 14.82      | 0.043     |
| Total  | 7      | 33 (21-45)     | 99.7                | 1778.21 | P<0.001          | 0.27       | 0.798     |
| ATP III| 2      | 12 (8-33)      | 99.4                | 155.95 | P<0.001            | --         | --         |
| 4      | NCEP   | 1              | 9 (7-10)            |     |                    | --         | --         |
| IDF    | 0      | --             | --                  |     |                    | --         | --         |
| Total  | 3      | 11 (2-20)      | 98.7                | 156.32 | P<0.001            | 0.50       | 0.702     |
| ATP III| 1      | 32 (29-35)     | --                  |     |                    | --         | --         |
| 5      | NCEP   | 3              | 35 (5-66)           | 99.9 | 1497.04            | P<0.001    | 3.23       | 0.191     |
| IDF    | 2      | 45 (6-84)      | 99.8                | 468.42 | P<0.001            | --         | --         |
| Total  | 6      | 38 (20-56)     | 99.8                | 2181.50 | P<0.001          | 3.94       | 0.017     |
| ATP III| 15     | 29 (22-36)     | 99.3                | 2009.74 | P<0.001          | 1.96       | 0.071     |
| 6      | NCEP   | 20             | 29 (24-34)          | 99.4 | 2940.51            | P<0.001    | 1.08       | 0.296     |
| IDF    | 13     | 38 (32-43)     | 99.2                | 1570.91 | P<0.001          | 1.22       | 0.250     |
| WHO    | 2      | 30 (7-53)      | 99.4                | 155.40 | P<0.001            | --         | --         |

On the basis classification of geography, Iran is divided into 5 regions. Region 1 includes the provinces of Tehran, Qazvin, Golestan, Mazandaran, Semnan, Alborz, and Qom. Region 2 includes Isfahan, Fars, Bushehr, Chaharmahal and Bakhtiari, Hormozgan and Kohkiluyeh and Boyerahmad provinces. Region 3 contains the provinces of East Azerbaijan, West Azerbaijan, Ardebil, Zanjan, Gilan, and Kurdistan. Region 4 covers Kermanshah, Ilam, Lorestan, Hamedan, Markazi and Khuzestan, and, region 5 includes Razavi Khorasan, South Khorasan, North Khorasan, Kerman, Yazd and Sistan-Baluchestan provinces.

**Discussion**

Metabolic syndrome or insulin resistance syndrome is a collection of risk factors for heart diseases including abnormal blood lipids (dyslipidemia), glucose intolerance, central obesity, and hypertension (26). Genetic, metabolic, stress and environmental factors such as the diet play an important role in the development of the syndrome. Since MetS significantly increase the risk of various diseases such as cardiovascular disease, diabetes, ovarian cysts, fatty liver, asthma (13) and some cancers (14), investigating the prevalence of this syndrome seems to be essential in different populations.

According to results of our study, the overall weighted prevalence of this syndrome, excluding the diagnostic criteria was 31% (CI 95%: 28-35). The prevalence of MetS in few studies is between 10% and 30%; however, many other studies have estimated a prevalence of more than 30%. In line with this finding, a high incidence of this syndrome has been observed in the neighboring countries of Iran such as Pakistan and Turkey (27, 28). Based on the results of this study in Iranian population, the prevalence of the syndrome is higher than many countries, including France (25% in men and 15.3% wom-
en) (29), America (22.9%) (30), Portugal (27.6%) (31), Spain (26.6%) (32) and Italy (22% in men and 18% in women) (33). However, the prevalence of the MetS in North African countries (30%) (34), Turkey (36.6%) (35) and Colombia (34.8%) (36) is similar to Iran. The difference in the prevalence of MetS across the countries can be primarily attributed to the differences in lifestyles and culture (37).

Based on the diagnostic criteria, the highest prevalence of MetS was based on the IDF with a value of 38% (CI 95%: 7-53%) and the lowest prevalence was obtained from the ATPIII 29% (CI 95%: 7-53%) and NCEP/ATPIII 29% (CI 95%: 7-53%). According to the WHO criteria, the prevalence of this syndrome was calculated 30% (CI 95%: 7-53%). The results of several studies have indicated a higher prevalence of the syndrome based on IDF criterion compared to the other criteria (38, 39). For instance, a high prevalence of MetS according to IDF criteria was reported in a recent study in Germany. In this study, the prevalence of this syndrome according to criteria of IDF was 51% (40). In a study conducted in American adults, the prevalence of the MetS according to IDF criteria was 39% (38.1% in women and 39.9% men) (41). The reason for high prevalence of the MetS using the IDF criteria can be due to a lower cutoff point of waist circumference (39, 42, 43) and tighter criteria for fasting glycaemia (44).

However, a lower prevalence of MetS according to IDF criteria was also reported (45). The highest and lowest prevalence of the MetS were defined by WHO and IDF criteria, respectively (46). The discrepancy between the results of different studies can be contributed to difference in abdominal obesity and waist circumference in different populations.

The prevalence of the syndrome in Iran differs from the neighbors from 20%-37.2% and 32%-47% in men and women, respectively (45). Total prevalence of MetS in men and women were 28% and 38%, respectively. In all diagnostic criteria, the prevalence of the MetS was significantly higher in women than men. Similar to our findings, reports from Unite state of America (Native and Mexican American), Turkey, Oman and India demonstrate a higher rate of MetS prevalence in women compared to men (47). A higher rate of the MetS in women can be attributed to increasing of abdominal obesity in this group. Increased abdominal obesity is due to a lower level of physical activity, higher order of birth and menopause status (48).

The prevalence of MetS is highly depended on age has been observed in many studies (48-50). The results of this study also show that the prevalence of MetS in aged 4-90 yr in both sexes and in different regions varies from 1% to 74%.

Most of gender difference in the prevalence of the MetS is observed in higher age groups. In this meta-analysis, the prevalence rate of MetS using a random effects model, at ages less and more than 19 yr were 18% (CI 95%: 12% - 25%) and 31% (CI 95%: 28% - 34%), respectively. The results show an upward trend according to age in both sexes and the prevalence was enhanced in all diagnostic criteria. In agreement with our findings, the prevalence of the syndrome was less than 10% for men and women in the age group below 30 yr, but the prevalence has increased in age group 60-69 yr more than 38% and 67% in men and women, respectively (51). In a French population, the prevalence of this syndrome was less than 5.6% in the age group 30-39 yr, but it was increased to over 17.5% in the age group over 60 yr. In addition, in a study in America, the prevalence of MetS were 7%, 44% and 42% in the age group under 30 yr, 69-60 yr and older than 70 yr, respectively (52). In contrast to our results, the prevalence of MetS decreased from 25.5% to 22.9%. Furthermore, in this study a significant increase was calculated in the prevalence of the MetS with increasing age in women (P=0.005) but not in men (P=0.54) (30).

Based on the geographical region, the highest and lowest prevalence of the MetS were observed in the regions 5 (38%) and 4 (11%), respectively. A relatively large change in the prevalence of the syndrome has been observed in region 4 in comparison to the other regions. More specifically, the residents of Kerman, Te-
hren, Shiraz, Tabriz and Zahedan, Iran demonstrated a higher prevalence of the MetS based on all diagnostic criteria. The discrepancies among the regions may be associated with different factors including lifestyle, socioeconomic status, nutritional status and education of the residents of these areas. It is of note that the modern lifestyles such as consuming fast foods of high-calorie play an important role in development of the MetS and obesity.

Advantages and Limitations

The high heterogeneity observed among studies could be regarded as a limitation of the present study. Probably the small sample size of a few of the studies included in the current review could be regarded as the reason of the heterogeneity. Second, due to limited access to some Persian articles, some studies might have been missed. Nevertheless, the main strengths of this study were that most of the included studies had large sample sizes. Two investigators independently extracted data and reviewed the articles to obtain data accurately.

Conclusion

The prevalence of the MetS in Iranian population is higher than the western counterparts. There is an emerging high prevalence of MetS in Iranian women population. In addition, the prevalence of MetS increases with increasing the age in this population. Therefore, to reduce the risk of cardiovascular events in Iranian population, screening and early detection of risk factors for MetS are suggested.

Ethical considerations

Ethical issues (Including informed consent, plagiarism, misconduct, data fabrication and/or falsification, double publication and/or submission, redundancy, etc.) have been completely observed by all of the authors.

Acknowledgements

We would like to acknowledge of the Social Determinants of Health Research Center, Kurdistan University of Medical Sciences. The authors declare that there is no conflict of interest.

References

1. Duc Son LNT, Kunii D, Hung NT, Sakai T, Yamamoto S (2005). The metabolic syndrome: prevalence and risk factors in the urban population of Ho Chi Minh City. Diabetes Res Clin Pract, 67(3): 243-50.
2. Mahan LK, Escott-Stump S, Raymond JL, Marie V (2012). Kruse’s Food & the Nutrition Care Process. 13th ed. Elsevier Saunders.
3. Ziccardi P, Nappo F, Giugliano G et al (2002). Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation, 105(7): 804-9.
4. Ghaffari M-A, Payami S-A, Payami SP, Ashtary-Larky D, Nikzamir A, Mohammadzadeh G (2016). Evaluation of Insulin Resistance Indices in Type 2 Diabetic Patients Treated with Different Anti-Diabetic Drugs. Open J Endocr Metab Dis, 6(02): 95-101.
5. Kim MH, Kim MK, Choi BY, Shin YJ (2004). Prevalence of the metabolic syndrome and its association with Cardiovascular Disease in Korea. J Korean Med Sci, 19(2): 195-201.
6. Keller KB, Lemberg L (2003). Obesity and the metabolic syndrome. Am J Crit Care, 12(2):167-70.
7. Alberti G, Zimmet P, Shaw J, Grundy SM (2006). IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation. Available from: http://www.idf.org/metabolic-syndrome.
8. Kassi E, Pervandou P, Kaltzas G, Chrousos G (2011). Metabolic syndrome: definitions and controversies. BMC Med, 9: 48.
9. Grundy SM, Cleeman JI, Daniels SR et al (2005). Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 112(17): 2735-52.

Available at: http://ijph.tums.ac.ir
10. Geffken DF, Cushman M, Burke GL, Polak JF, Sakkinen PA, Tracy RP (2001). Association between physical activity and markers of inflammation in a healthy elderly population. *Am J Epidemiol*, 153(3): 242-50.

11. Womack CJ, Ivey FM, Gardner AW, Macko RF (2001). Fibrinolytic response to acute exercise in patients with peripheral arterial disease. *Med Sci Sports Exerc*, 33(2): 214-9.

12. Gaeini A, Sheykhllesam Vatani D et al (2008). Effect of endurance training and a detraining period on lipid peroxidation and antioxidant system in wistar rats. *Journal of Movement Science & Sports*, 6(11): pp. 51-63.

13. Brumpton BM, Camargo CA Jr, Romundstad PR, Langhammer A, Chen Y, Mai XM (2013). Metabolic syndrome and incidence of asthma in adults: the HUNT study. *Eur Respir J*, 42(6):1495-502.

14. Braun S, Bitton-Worms K, LeRoith D (2011). The Link between the Metabolic Syndrome and Cancer. *Int J Biol Sci*, 7(7):1003-15.

15. Salem Z, Vaziniejad R (2007). Prevalence of obesity and metabolic syndrome among adolescent girls in Rafsanjan, 2007. *Iranian Journal of Diabetes and Metabolism*, 7(2): 205-13.

16. Sharifi F, Mousavinasab S, Saeini M, Dinmohammadi M (2009). Prevalence of Metabolic Syndrome in an Adult Urban Population of the West of Iran. *Exp Diabetes Res*, 2009: 136501.

17. Shahbazian H, Latifi SM, Jalali MT, et al (2013). Metabolic syndrome and its correlated factors in an urban population in South West of Iran. *J Diabetes Metab Disord*,12:11.

18. Salem Z, Vaziniejad R (2010). Prevalence of the metabolic syndrome components among 7–11 year-old children in Rafsanjan, 2008. *Iranian Journal of Nutrition Sciences & Food Technology*, 5(2): 63-71.

19. Saberi H, Moraveji A, Parastouie K (2009). Metabolic syndrome among professional bus and truck drivers in Kashan, 2008. *Iranian South Medical Journal*, 12(2):126-32 (In persian).

20. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*, 151(4):264-9.

21. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. *Stat Med*, 21(11):1539-58.

22. Cochran WG (1954). The combination of estimates from different experiments. *Biometrics*, 10(1):101-29.

23. Jalalzadeh M, Mohammad M, Mirzamohammadi F, Ghadiani MH (2011). Prevalence of metabolic syndrome in a hemodialysis population. *Iran J Kidney Dis*, 5(4): 248-54.

24. Gharipour M, Kelishadi R, Toghianifar N et al (2011). Socioeconomic Disparities and Smoking Habits in Metabolic Syndrome: Evidence from Isfahan Healthy Heart Program. *Iran Red Crescent Med J*,13(8):537-43.

25. Regions of Iran [Internet]. Wikipedia [cited 28 Jun 2016]. Available from: https://en.wikipedia.org/wiki/Regions_of_Iran.

26. Laura J (2016). Metabolic syndrome. https://medlineplus.gov/ency/article/007290.htm.

27. Gundogán K, Bayram F, Capak M et al (2009). Prevalence of metabolic syndrome in the Mediterranean region of Turkey: evaluation of hypertension, diabetes mellitus, obesity and dyslipidemia. *Metab Syndr Relat Disord*, 7(5):pp. 427-34.

28. Hydrie MZ, Shera AS, Fawwad A, Basit A, Hussain A (2009). Prevalence of metabolic syndrome in urban Pakistan (Karachi): comparison of newly proposed International Diabetes Federation and modified Adult Treatment Panel III criteria. *Metab Syndr Relat Disord*, 7(2): 119-24.

29. Wagner A, Dallongeville J, Haas B et al (2012). Sedentary behaviour, physical activity and dietary patterns are independently associated with the metabolic syndrome. *Diabetes Metab*, 38(5): 428–35.

30. Beltrán-Sánchez H, Harhay MO, Harhay MM, McElligott S (2013). Prevalence and Trends of Metabolic Syndrome in the Adult U.S. Population, 1999–2010. *J Am Coll Cardiol*, 62(8): 697-703.

31. Fonseca MJ, Gaio R, Lopes C, Santos AC (2012). Association between dietary patterns and metabolic syndrome in a sample of Portuguese adults. *Nutr J*, 11: 64.

32. Corbaton-Anchuelo A, Martínez-Larrad MT, Fernandez-Perez C et al (2013). Metabolic syndrome, adiponectin, and cardiovascular
risk in Spain (the Segovia study): impact of consensus societies criteria. Metab Syndr Relat Disord, 11(5): 309-18.
33. Giampaoli S, Stanler J, Donfrancesco C et al (2009). The metabolic syndrome: a critical appraisal based on the CUORE epidemiologic study. Prev Med, 48(6): 525–31.
34. Belkh H, Ben Ali S, Aounallah-Shkiri H et al (2013). Prevalence and determinants of the metabolic syndrome among Tunisian adults: results of the Transition and Health Impact in North Africa (TAHINA) project. Public Health Nutr, 16(4): 582–90.
35. Wang GR, Li I, Pan YH et al. (2013). Prevalence of metabolic syndrome among urban community residents in China. BMC Public Health, 13:599.
36. Pinzon JB, Serrano NC, Diaz LA et al (2007). Impact of the new definitions in the prevalence of the metabolic syndrome in an adult population at Bucaramanga, Colombia. Biomedica, 27(2):172–9.
37. Hajian-Tilaki K, Heidari B, Firouzjahi A, Bagherzadeh M, Hajian-Tilaki A, Halalikhor S (2014). Prevalence of metabolic syndrome and the association with socio-demographic characteristics and physical activity in urban population of Iranian adults: a population-based study. Diabetes Metab Syndr, 8(3):170-6.
38. Rathmann W, Haastert B, Icks A et al (2006). Prevalence of the Metabolic Syndrome in the Elderly Population According to IDF, WHO, and NCEP Definitions and Associations With C-Reactive Protein: the KORA Survey 2000. Diabetes Care, 29(2): 461.
39. Deepa M, Farooq S, Datta M, Deepa R, Mohan V (2007). Prevalence of metabolic syndrome using WHO, ATPIII and IDF definitions in Asian Indians: the Chennai Urban Rural Epidemiology Study (CURES- 34). Diabetes Metab Res Rev, 23(2):127-34.
40. Obeidat A, Ahmad MN, Haddad FH, Azzeh FS (2015). Alarming high prevalence of metabolic syndrome among Jordanian adults. Pak J Med Sci, 31(6): 1377–82.
41. Ford ES (2005). Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care, 28(11): pp. 2745-9.
42. Zabetian A, Hadaegh F, Azizi F (2007). Prevalence of metabolic syndrome in Iranian adult population, concordance between the IDF with the ATPIII and the WHO definitions. Diabetes Res Clin Pract, 77(2): 251–7.
43. Chuangsarnam S, Rattanamongkoulgul S, Villarroel A (2010). Association between metabolic syndrome and risk of cardiovascular disease, using different criteria and stratified by sex. Int J Diabetes Mellit, 2(2): 78-82.
44. Kaur J (2014). A Comprehensive Review on Metabolic Syndrome. Cardiol Res Pract, Volume 2014 (2014): p. 21.
45. Mabry RM, Reeves MM, Eakin EG, Owen N (2010). Gender differences in prevalence of the metabolic syndrome in Gulf Cooperation Council Countries: a systematic review. Diabet Med, 27(5): 593-7.
46. Ko GT, Cockram CS, Chow CC et al (2006). Metabolic syndrome by the international diabetes federation definition in Hong Kong Chinese. Diabetes Res Clin Pract, 73(1): 58-64.
47. Eckel RH, Grundy SM, Zimmet PZ. (2005). The metabolic syndrome. Lamed, 365(9468): 1415-28.
48. Hajian-Tilaki KO, Heidari B (2007). Prevalence of obesity, central obesity and the associated factors in urban population aged 20-70 years, in the north of Iran: a population-based study and regression approach. Obes Res, 8(1): 3-10.
49. Rashidi H, Payami SP, Latifi SM et al (2014). Prevalence of metabolic syndrome and its correlated factors among children and adolescents of Ahvaz aged 10 – 19. J Diabetes Metab Disord, 13: 53.
50. Delavar MA, Lye M-S, Khor GL et al (2009). Prevalence of metabolic syndrome among middle aged women in Babol, Iran. Southeast Asian J Trop Med Public Health, 40(3): 612-28.
51. Azizi F, Salehi P, Etemadi A, Zahedi Asl S (2003). Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract, 61(1): 29-37.
52. Ford ES, Giles WH, Dietz WH (2002). Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA, 287(3): 356-9.
53. Jalali R, Vasheghani M, Dabbaghmanesh M, Ranjbar Omrani G (2009). Prevalence of
Metabolic Syndrome Among Adults in a Rural Area. *Iranian Journal of Endocrinology and Metabolism*, 11(4): 405-14 (In Persian).

54. Sadrbafoghi SM , Salari M , Rafiee M et al (2006). Prevalence and criteria of metabolic syndrome in an urban population: Yazd Healthy Heart Project. *Tehran Univ Med J*, 64 (10): 90-6.

55. Ghergherechi R, Razzaghy Azar M (2010). Prevalence of Metabolic Syndrome in Obese Children and Adolescents. *Med J Tabriz Univ Med Sci Health Serv*, 32(3): 57-61 (In Persian).

56. Javadi H, Hashemipour S, Abbasi M, Javadi A (2014). Prevalence of metabolic syndrome and its components in over 24 years old population of Qazvin (2012). *Journal of Qazvin University of Medical Sciences*, 18(3): 7-11 (In Persian).

57. Marjani A, Mojjerloo M (2011). The metabolic syndrome in type 2 diabetic subjects in Gorgan, Iran. *J Pak Med Assoc*, 61(5): 458-61.

58. Jouyandeh Z, Nayehzadeh F, Qorbani M, Asadi M (2013). Metabolic syndrome and menopause. *J Diabetes Metab Disord*, 12(1): p. 1.

59. Hadaegh F, Zabetian A, Tohidi M, Ghasemi A, Sheikholeslami F, Azizi F (2009). Prevalence of Metabolic Syndrome by the Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions and their Association with Coronary Heart Disease in an Elderly Iranian Population. *Ann Acad Med Singapore*, 38(2):142-9.

60. Maharlouei N, Bellissimo N, Ahmadi SM, Lankarani KB (2013). Prevalence of metabolic syndrome in pre- and postmenopausal Iranian women. *Climacteric*, 16(5): 561–7.

61. Mardani M, Rafiee E, Ebrahizadeh F, Baba H, Balavar S, Ali Mohammadi M (2015). Prevalence of metabolic syndrome among students of Lorestan University of Medical Sciences. *Medical Journal of Masihabad University of Medical Sciences*, 57(8): 918-25 (In persian).

62. Sarrafzadegan N, Gharipour M, Ramezani MA et al (2011). Metabolic syndrome and health-related quality of life in Iranian population. *J Res Med Sci*, 16(3): 254-61.

63. Kaykhaei M, Hashemi M, Narouie B et al (2012). Prevalence of Metabolic Syndrome in Adult Population from Zahedan, Southeast Iran. *Iran J Public Health*, 41(2): 70-6.

64. Fakhhrzadeh H, Ebrahim Pour R, Nouri M et al (2004). Evaluation of prevalence of the metabolic syndrome in inhabitants of Tehran university of medical sciences population lab. *IJDDL*, 3: 71-80.

65. Foroozanfar Z, Najafipour H, Khajani N, Bahrampour A, Ebrahim H (2015). The Prevalence of Metabolic Syndrome According to Different Criteria and its Associated Factors in Type 2 Diabetic Patients in Kerman, Iran. *Iran J Med Sci*, 40(6): pp. 522-5.

66. Keykha M, Janghorbani M, Amini M (2013). Prevalence and Risk Factors of Diabetes, Pre-Diabetes and Metabolic Syndrome in First-Degree Relatives of Patients with Type II Diabetes. *Journal of Kerman University of Medical Sciences*, 20(2): 115-28.

67. Marjani A, Hezarkhani S, Shahini N (2012). Prevalence of metabolic syndrome among fars ethnic women in North East of Iran. *World Journal of Medical Sciences*, 7(1): 17-22.

68. Esmailnasab N, Moradi G, Delaveri A (2012). Risk Factors of Non-Communicable Diseases and Metabolic Syndrome. *Iran J Public Health*, 41(7): 77-85.

69. Marjani A, Moghasemi S (2012). The Metabolic Syndrome among Postmenopausal Women in Gorgan. *Int J Endocrinol*, 2012: 953627.

70. Ostovaneh M, Zamani F, Sharaftkhah M et al (2014). Prevalence of metabolic syndrome in Amol and Zahedan, Iran: a population based study. *Arch Endocrinol Med Sci*, 7(7): 477-82.

71. Ghorbani R, Abtahi naeini B, Eskandarian R, Rashidy-Pour A, Khamseh ME, Malek M. (2012). Prevalence of metabolic syndrome according to ATPIII and IDF criteria in the Iranian population. *Koomesh*, 14(1): 65-75.

72. Tabatabaie AH, Shafiekhmani M, Nasibatkon AA et al (2015). Prevalence of metabolic syndrome in adult population in Shiraz, southern Iran. *Diabetes Metab Syndr*, 9(3): 153-6.

73. Mahjoub S, Haji Ahmadi M, Faramarzi M, Ghorbani H, Moazzezi Z (2012). The prevalence of metabolic syndrome according to the Iranian Committee of Obesity and ATP III criteria in Babol, North of Iran. *Caspian J Intern Med*, 3(2): 410-6.
74. Moini A, Javanmard F, Eslami B, Aletaha N (2012). Prevalence of metabolic syndrome in polycystic ovarian syndrome women in a hospital of Tehran. *Iran J Reprod Med*, 10(2): 127-30.

75. Ebrahimi-Mameghani M, Naimi AR F, Nourmohammadi M, Azabdaftari N (2011). Prevalence of Metabolic syndrome in Tabriz city firefighters. *Journal of Kermanshah University of Medical Sciences*, 15(4): 296-302 (In Persian).

76. Mohebbi I, Saadat S, Aghassi M, Shekari M, Matinkhah M, Sehat S (2012). Prevalence of Metabolic Syndrome in Iranian Professional Drivers: Results from a Population Based Study of 12,138 Men. *Plos One*, 7(2): e31790.